The 'Sell' rating maintained by Rosenblatt indicates a negative outlook for CME Group. However, the increase in price target from $173 to $180 suggests that the analyst sees some potential for the stock's price to rise in the short term, despite the overall negative rating. This could create some uncertainty among investors, potentially leading to short-term price volatility.